ChemPartner
22.12.2023 22:02:41 CET | ACCESS Newswire | Press release
Newly-launched database offers easier access to diverse tumor models and unveils the path to pharmaceutical breakthroughs
SHANGHAI, CHINA / ACCESSWIRE / December 22, 2023 / ChemPartner, a global leader in drug discovery and development services, today announced the launch of its long-awaited Biology Database. This innovative platform serves as a centralized hub, empowering ChemPartner's clientele with seamless access to a wealth of information on the organization's cutting-edge preclinical platforms. The database includes 800+ tumor models, 30+ cancer types, 20,000 genes, 2,300+ pathways, 1,800 SoC data from literature (500 internal), and 30+ analytic modules.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Screenshot of the online Biology Database from ChemPartner
ChemPartner's renowned biology and pharmacology department, known for its vanguard oncology, immunology, CNS, and metabolic services, has curated an extensive collection of in vitro and in vivo models. The database boasts over 2,000 biochemistry assays, 800 cell lines, 500 patient-derived xenograft (PDX) models, 350 cell-derived xenograft (CDX) models, and 50 syngeneic models. Each model is meticulously characterized with comprehensive data encompassing genomics, pharmacology, histopathology, and relevant clinical information.
Cell Line Models - ChemPartner Biology Database
To ensure a smooth and efficient rollout of this substantial volume of data, the database will be introduced in stages. We are delighted to announce that the first stage, featuring cell line data, is now live on https://database.chempartner.com. Subsequent stages will include CDX, syngeneic, and PDX models, followed by biochemistry data.
The Biology Database, a flagship online collaborative platform, prominently features the Tumor Model Database. This revolutionary resource offers an array of features, including:
- Unified Data Hub: Integration of dispersed tumor model data into a centralized database for efficient management and retrieval, simplifying user access to diverse tumor models.
- Detailed Annotations: Each model is accompanied by intricate annotations including genomics, pathology, and pharmacology data, enabling rapid understanding of model characteristics and suitability for specific research needs.
- Rapid Search and Filtering: Multidimensional search and filtering capabilities empower researchers to swiftly locate models based on cancer type, genomic features, drug sensitivity, and more.
- Data Analysis and Mining: Robust tools facilitate tasks like drug mechanism analysis and biomarker discovery through differential gene expression and drug sensitivity analyses, supporting informed research decisions.
- Data Visualization: Intuitive charts, statistics, and visualization tools present complex data clearly and concisely, aiding in model selection and analysis.
Dr. Lilly Xu, President of Shanghai ChemPartner, expressed enthusiasm about the launch saying, "We are excited to provide our customers with access to this powerful new resource. This comprehensive database will make it easier for our customers to find and use the right models for their research, propelling drug development towards new heights with better precision, efficacy, and efficiency."
-
About ChemPartner
ChemPartner is a leading global CRO and CDMO providing drug discovery, development, and manufacturing services to the pharmaceutical and biotechnology industries. With a team of over 2,000 scientists across multiple countries, ChemPartner offers a comprehensive range of services including preclinical pharmacology, toxicology, drug metabolism and pharmacokinetics, chemistry development, and biologics development. For more information, please visit https://chempartner.com and connect with ChemPartner on LinkedIn, X, and YouTube.
Contact Information
Sarah Stapleton
Marketing Director
news@chempartner.com
6504199974
Related Images
|
SOURCE: ChemPartner
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Continent 8 and FuturePath AI Launch Future8: Accountable AI for Regulated Industries29.9.2026 15:00:00 CEST | Press release
LISBON, PT / ACCESS Newswire / September 29, 2026 / Continent 8 Technologies and FuturePath AI today launched Future8, an AI-native operating company built for regulated operators, formed as a joint venture between the two companies. Announced at SBC Summit Lisbon, Future8 combines FuturePath's enterprise AI applications platform with Continent 8's licensed global operating footprint, enabling the iGaming industry to deploy auditable AI without compromising compliance, data sovereignty and operational control. Built for highly regulated environments, Future8 enables operators to move from AI experimentation to production deployment by embedding governance, approvals and auditability into every workflow from day one. Continent 8 brings licensed data centers and a private global network spanning more than 100 locations, built over 28 years serving the biggest iGaming and online brands, along with AI-enabled Global Capability Centers in India, the Philippines and Bulgaria. The company als
Europe SPAC Summit 2026 Invites European Private Companies to Explore the SPAC Path to U.S. Public Markets29.9.2026 15:00:00 CEST | Press release
NEW YORK, NY AND ZURICH, SWITZERLAND / ACCESS Newswire / September 29, 2026 / A growing number of European companies in frontier technologies, critical minerals, advanced manufacturing, defense tech, energy, and consumer sectors are evaluating a merger with a special purpose acquisition company (SPAC) as a faster route to a U.S. listing, a valuation that reflects global investor demand, and access to follow-on capital. The Europe SPAC Summit 2026 (ESPAC'26), co-hosted by AUM Advisors and MBP Global, is inviting the CEOs, CFOs, founders, and board members of late-stage European private companies to The Dolder Grand in Zurich on Thursday, December 10, 2026, to learn how the process works and to meet the investment bankers, institutional investors, and SPAC sponsors who make these transactions happen. Attendance is by invitation only and free of charge for qualified companies. Europe's recent de-SPACs show what is possible. Kyivstar, Ukraine's largest mobile operator, listed on Nasdaq thr
Gedeon Richter Launches Online Platform for Transdiagnostic Global Impression Scales and New Caregiver Book at Next Step Conference29.9.2026 14:00:00 CEST | Press release
BUDAPEST, HU / ACCESS Newswire / September 29, 2026 / Gedeon Richter welcomed 145 participants from 27 countries to the latest edition of Next Step, the company's international conference for psychiatrists, held in September at the Hungarian Academy of Sciences. "At Gedeon Richter, we see partnerships as a cornerstone of advancing psychiatric care. By supporting healthcare professionals, patients, and caregivers alike, we can help create meaningful improvements in outcomes, functioning, and quality of life for people living with mental health conditions," said Kristóf Kóczián, Head of Global Business Development and CNS Business Unit at Gedeon Richter in his opening speech. The scientific programme explored how psychiatric care can move beyond diagnostic labels and adopt a more personalized, measurement-based approach. The presentations highlighted how personalized, measurement-based care can be integrated into everyday clinical practice, with a focus on cognitive symptoms, treatment-r
U.S. Polo Assn. Brings 'Game On' to Life with the 2026 Fall-Winter Global Collection29.9.2026 13:00:00 CEST | Press release
WEST PALM BEACH, FL / ACCESS Newswire / September 29, 2026 / U.S. Polo Assn.®, the official sports brand of the United States Polo Association (USPA), has launched its 2026 Fall-Winter Global Collection, a modern expression of American style rooted in the heritage and energy of the sport of polo. Photographed in the beautiful countryside of Millbrook, New York, the campaign blends the sophistication of New York lifestyle with the authenticity of Hudson Valley's equestrian heritage. From local gathering places and small-town Americana to scenic polo fields and countryside settings, the location creates a natural backdrop for ‘Game On,' a seasonal story inspired by campus life, sport, and polo's enduring style. "The 2026 Fall-Winter Global Collection reflects what makes U.S. Polo Assn. distinctive: an authentic connection to the sport, a modern American point of view and style designed for real life," said J. Michael Prince, President and CEO of USPA Global, the company that manages and
Akkodis and Biolevate Partner to Accelerate AI-Powered Scientific, Regulatory and Technical Documentation in Highly Regulated Industries29.9.2026 06:45:00 CEST | Press release
ZURICH, SWITZERLAND / ACCESS Newswire / September 29, 2026 / Akkodis, a global leader in digital engineering consulting and part of the Adecco Group, and Biolevate, an AI-powered life sciences company, today announced a strategic partnership to accelerate AI-assisted scientific, regulatory and technical documentation in highly regulated industries. Initially launching in France and Belgium, with plans for expansion into additional markets, the partnership combines Biolevate's AI platform with Akkodis' engineering, validation and regulatory expertise to help organizations improve compliance, reduce documentation burdens and accelerate innovation. In highly regulated industries, scientific, technical and compliance-related documentation is critical to product approvals, quality, patient safety and operational compliance. As documentation volumes increase, organizations continue to struggle with manual, resource-intensive processes that are difficult to scale. The result is a pressing nee
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom